Knight Therapeutics Inc.
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
0/10
|
0 | 31.52 | -100% | 13.91 | -100% |
| P/S |
|
1.69 | 3.23 | -47.78% |
|
|
| P/BV |
|
0.5594 | 3.36 | -83.35% |
|
|
| P/FCF |
|
0 | 21.22 | -100% |
|
|
| Ev/Ebitda |
|
7.85 | 9.93 | -20.97% |
|
|
| Ev/S |
|
1.73 | 1.88 | -8.32% |
|
|
| Ev/FCF |
|
21.8 | 19.91 | 9.47% |
|
|
| E/P |
|
0 | 1.47 | -100% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
7/10
|
22.01 | 24.7 | -10.88% | 14.98 | +46.9% |
| ROE |
|
-1.7 | 13.11 | -112.99% |
|
|
| ROA |
|
-1.35 | 6.09 | -122.07% |
|
|
| ROIC |
|
0 | 15.56 | -100% |
|
|
| ROS |
|
-5.13 | 12.44 | -141.25% |
|
|
| ROCE |
|
2.21 | 15.21 | -85.47% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
8/10
|
1.17 | 6.21 | -81.24% | 1.72 | -32.22% |
| Nеt Debt/Ebitda |
|
0.1903 | -5.72 | -103.33% |
|
|
| Debt/Ratio |
|
0.0673 | 0.213 | -68.42% |
|
|
| Debt/Equity |
|
0 | 12.49 | -100% |
|
|
| Debt/Net Income |
|
-5 | 15.07 | -133.18% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0/10
|
0 | 1.76 | -100% | 0 | 0% |
| Number of years of dividend growth |
|
0 | 1.21 | -100% | ||
| DSI |
|
0 | 0.7783 | -100% |
|
|
| Average dividend growth |
|
0 | -269.81 | -100% |
|
|
| Average percentage for 5 years |
|
0 | 2.8 | -100% |
|
|
| Average percentage for payments |
|
50.73 | 246.95 | -79.46% |
|
|
| Difference from average difference in sector |
|
-1.76 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
10/10
|
409.27 | 132.71 | 208.39% | ||
| Growth impulse Ebitda in 5 years |
|
64.94 | 100.7 | -35.51% | ||
| Growth impulse Net Income in 5 years |
|
-184.89 | 116.53 | -258.66% | ||
| Growth impulse FCF in 5 years |
|
1043.75 | 88.28 | 1082.32% | ||
| Growth impulse EPS in 5 years |
|
-211.32 | 217.84 | -197.01% |
IP Score
4.77/10
